Arcus Biosciences (RCUS) Non Operating Income (2017 - 2026)
Arcus Biosciences (RCUS) posted quarterly Non Operating Income of $6.0 million for Q1 2026, down 40.0% year-over-year from $10.0 million in Q1 2025, and down 25.0% quarter-over-quarter from $8.0 million in Q4 2025.
Arcus Biosciences (RCUS) Non Operating Income (2017 - 2026) Analysis & Trends
Arcus Biosciences' Non Operating Income history runs 10 years deep, the most recent figure standing at $6.0 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 40.0% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $29.0 million (down 36.96% YoY), while the FY2025 annual figure was $33.0 million, down 31.25% from the prior year.
- Non Operating Income for Q1 2026 stood at $6.0 million, down from $8.0 million in the prior quarter.
- The five-year high for Non Operating Income was $13.0 million in Q2 2024, with the low at $191000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $8.0 million (2023), against an average of $8.2 million.
- The sharpest annual moves came in 2023 and 2025: Non Operating Income surged 4088.48% in 2023, then slumped 46.15% in 2025.
- Arcus Biosciences' Non Operating Income stood at $7.0 million in 2022, then jumped by 57.14% to $11.0 million in 2023, then dropped by 9.09% to $10.0 million in 2024, then slipped by 20.0% to $8.0 million in 2025, then retreated by 25.0% to $6.0 million in 2026.
- Business Quant data shows RCUS's Non Operating Income at $6.0 million in Q1 2026, $8.0 million in Q4 2025, and $7.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Arcus Biosciences | 3.74 Bn | 3.04 Bn | - | 5.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.00 Mn |
| Mar 31, 2026 | 6.00 Mn |
| Dec 31, 2025 | 8.00 Mn |
| Sep 30, 2025 | 7.00 Mn |
| Jun 30, 2025 | 8.00 Mn |
| Mar 31, 2025 | 10.00 Mn |
| Dec 31, 2024 | 10.00 Mn |
| Sep 30, 2024 | 13.00 Mn |
| Jun 30, 2024 | 13.00 Mn |
| Mar 31, 2024 | 12.00 Mn |
| Dec 31, 2023 | 11.00 Mn |
| Sep 30, 2023 | 11.00 Mn |
| Jun 30, 2023 | 9.00 Mn |
| Mar 31, 2023 | 8.00 Mn |
| Dec 31, 2022 | 7.00 Mn |
| Sep 30, 2022 | 5.00 Mn |
| Jun 30, 2022 | 2.00 Mn |
| Mar 31, 2022 | 191,000.00 |
| Dec 31, 2021 | 519,000.00 |
| Sep 30, 2021 | 161,000.00 |